This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Somnomed Raises AU$5.8 Million in Institutional Entitlement Offer; AU$16.8 Million Retail Component to Launch April 16 MT
SomnoMed Lowers Earnings, Revenue Guidance for Fiscal 2024; to Launch AU$22.6 Million Entitlement Offer MT
Somnomed Requests Voluntary Share Suspension Continuation MT
Wilsons Downgrades Somnomed to Marketweight From Overweight; Price Target is AU$0.45 MT
SomnoMed Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
SomnoMed Appoints Co-CEOs MT
SomnoMed Grows Fiscal Q1 Revenue MT
SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director CI
Transcript : SomnoMed Limited, 2023 Earnings Call, Aug 31, 2023
SomnoMed Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Somnomed Limited Announces Executive Changes CI
SomnoMed Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
SomnoMed Limited Reaffirms Earnings Guidance for the Year 2023 CI
Transcript : SomnoMed Limited, 2022 Earnings Call, Aug 23, 2022
Somnomed Fiscal Q4 Revenue Rises 32% MT
Transcript : SomnoMed Limited, H1 2022 Earnings Call, Feb 22, 2022
SomnoMed Introduces Rest Assure CI
SomnoMed Limited Provides Earnings Guidance for the Second Half of Fiscal Year 2022 and Reaffirms Earnings Guidance for the Fiscal Year 2022 CI
SomnoMed Limited Reports Earnings Results for the Half Year Ended December 31, 2021 CI
SomnoMed Develops Technology-Enabled Oral Appliance MT
SomnoMed Limited Announces World First Technology Enabled Oral Appliance CI
Transcript : SomnoMed Limited - Shareholder/Analyst Call
SomnoMed : Fiscal Q1 Revenue Rises 14%; Shares Climb 6% MT
ADDvantage Technologies : Names Michael Rutledge Finance Chief MT
Transcript : SomnoMed Limited, 2021 Earnings Call, Aug 24, 2021
Chart SomnoMed Limited
More charts
SomnoMed Limited is an Australia-based company, which is engaged in producing and selling devices for the oral treatment of sleep-related disorders. The Company provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is focused on the commercialization of the SomnoDent and other oral devices for sleep-related disorders. The Company’s segments include North America, Europe, Asia Pacific, CORE, and RSS. Its SomnoDent product line includes SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, SomnoDent Fusion, Herbst Advance Elite and Herbst Advance. Its SomMorning Repositioner is designed to help return their mandible back to its pre-treatment centric position. Its SomnoBrux Michigan splint is a custom fit, acrylic splint (dental guard) for upper teeth designed to protect the teeth from grinding and scraping during Bruxism. It also offers SomTabs, which are cleaning tablets that are developed to clean oral appliances.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.215 AUD
Average target price
1.26 AUD
Spread / Average Target
+486.05%
Consensus
  1. Stock Market
  2. Equities
  3. SOM Stock
  4. News SomnoMed Limited
  5. Somnomed Fiscal Q4 Revenue Rises 32%